{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,20]],"date-time":"2026-08-20T15:14:51Z","timestamp":1787238891858,"version":"build-2736575974"},"reference-count":189,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2008,7,1]],"date-time":"2008-07-01T00:00:00Z","timestamp":1214870400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Enfermedades Infecciosas y Microbiolog\u00eda Cl\u00ednica"],"published-print":{"date-parts":[[2008,7]]},"DOI":"10.1157\/13123842","type":"journal-article","created":{"date-parts":[[2009,1,6]],"date-time":"2009-01-06T12:37:50Z","timestamp":1231245470000},"page":"356-379","source":"Crossref","is-referenced-by-count":26,"title":["Tratamiento de las infecciones oportunistas en pacientes adultos y adolescentes infectados por el virus de la inmunodeficiencia humana en la era del tratamiento antirretroviral de gran actividad"],"prefix":"10.1016","volume":"26","author":[{"given":"Daniel","family":"Podzamczer","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1157\/13123842_bb0010","doi-asserted-by":"crossref","first-page":"1425","DOI":"10.1056\/NEJM198112103052401","article-title":"Pneumocystis carinii pneumonia and mucosal candidiasis in previously healthy homosexual men: evidence of a new acquired cellular immunodeficiency","volume":"305","author":"Gottlieb","year":"1981","journal-title":"N Engl J Med"},{"key":"10.1157\/13123842_bb0015","first-page":"252","article-title":"The management of opportunistic infections in the era of highly active antiretroviral therapy","volume":"2","author":"Ferrer","year":"2000","journal-title":"AIDS Rev"},{"key":"10.1157\/13123842_bb0020","doi-asserted-by":"crossref","first-page":"853","DOI":"10.1056\/NEJM199803263381301","article-title":"Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection","volume":"338","author":"Palella","year":"1998","journal-title":"N Engl J Med"},{"key":"10.1157\/13123842_bb0025","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1157\/13096749","article-title":"Spanish cohort of naive HIV-infected patients (CoRIS): rationale, organization and initial results","volume":"25","author":"Caro-Murillo","year":"2007","journal-title":"Enferm Infecc Microbiol Clin"},{"key":"10.1157\/13123842_bb0030","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1157\/13073938","article-title":"Caracter\u00edsticas y tendencias de los nuevos diagn\u00f3sticos de infecci\u00f3n por el virus de la inmunodeficiencia humana. Cohorte PISCIS","volume":"124","author":"Ja\u00e9n","year":"2005","journal-title":"Med Clin (Barc)"},{"key":"10.1157\/13123842_bb0035","doi-asserted-by":"crossref","first-page":"376","DOI":"10.1016\/S0213-005X(01)72670-5","article-title":"Tratamiento de las infecciones oportunistas en pacientes adultos y adolescentes infectados por el virus de la inmunodeficiencia humana en la era del tratamiento antiretroviral de gran actividad. Recomendaciones de GESIDA\/Plan Nacional sobre el SIDA","volume":"19","author":"Podzamczer","year":"2001","journal-title":"Enferm Infecc Microbiol Clin"},{"key":"10.1157\/13123842_bb0040","unstructured":"Panel de expertos de GESIDA y Plan Nacional sobre el Sida. Prevenci\u00f3n de las infecciones oportunistas en pacientes adultos y adolescentes infectados por el virus de la inmunodeficiencia humana en la era del tratamiento antirretrov\u00edrico de gran actividad. Recomendaciones del Grupo de Estudio del Sida (GESIDA)\/Plan Nacional sobre el Sida. Enferm Infecc Microbiol Clin. 2008; en prensa."},{"key":"10.1157\/13123842_bb0045","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1097\/00002030-199203000-00007","article-title":"Trimethoprim sulfamethoxazole versus pentamidine for Pneumocystis carinii pneumonia in AIDS patients: results of a large prospective randomized treatment trial","volume":"6","author":"Klein","year":"1992","journal-title":"AIDS"},{"key":"10.1157\/13123842_bb0050","doi-asserted-by":"crossref","first-page":"1500","DOI":"10.1056\/NEJM199011223232131","article-title":"Expert panel for corti costeroids as adjunctive therapy for Pneumocystis pneumonia. Consensus statement on the use of corticosteroids as adjunctive therapy for Pneumocystis pneumonia in the acquired immunodeficiency syndrome","volume":"323","author":"The National Institutes of Health University of California","year":"1990","journal-title":"N Engl J Med"},{"key":"10.1157\/13123842_bb0055","doi-asserted-by":"crossref","first-page":"912","DOI":"10.1093\/infdis\/170.4.912","article-title":"Adjunctive folinic acid with trimethoprim-sulfamethoxazole for Pneumocystis carinii pneumonia in AIDS patients is associated with an increased risk of therapeutic failure and death","volume":"170","author":"Safrin","year":"1994","journal-title":"J Infect Dis"},{"key":"10.1157\/13123842_bb0060","doi-asserted-by":"crossref","first-page":"801","DOI":"10.1097\/01.aids.0000168974.67090.70","article-title":"Severity and outcome of HIV-associated Pneumocystis pneumonia containing Pneumocystis jirovecii dihydropteroate synthase gene mutations","volume":"19","author":"Crothers","year":"2005","journal-title":"AIDS"},{"key":"10.1157\/13123842_bb0065","doi-asserted-by":"crossref","first-page":"792","DOI":"10.7326\/0003-4819-124-9-199605010-00003","article-title":"Comparison of three regimens for treatment of mild to moderate PCP in patients with AIDS","volume":"124","author":"Safrin","year":"1996","journal-title":"Ann Intern Med"},{"key":"10.1157\/13123842_bb0070","doi-asserted-by":"crossref","first-page":"776","DOI":"10.1056\/NEJM199009203231202","article-title":"Oral therapy for Pneumocystis carinii pneumonia in the acquired immunodeficiency syndrome. A controlled trial of trimethoprim sulfamethoxazole versus trimethoprim dapsone","volume":"323","author":"Medina","year":"1990","journal-title":"N Engl J Med"},{"key":"10.1157\/13123842_bb0075","doi-asserted-by":"crossref","first-page":"905","DOI":"10.1093\/clinids\/18.6.905","article-title":"Clindamycin and primaquine therapy for mild to moderate episodes of Pneumocystis carinii pneumonia in patients with AIDS: AIDS Clinical Trials Group 044","volume":"18","author":"Black","year":"1994","journal-title":"Clin Infect Dis"},{"key":"10.1157\/13123842_bb0080","doi-asserted-by":"crossref","first-page":"1521","DOI":"10.1056\/NEJM199305273282103","article-title":"Comparison of atovaquone (566C80) with trimethoprim sulfamethoxazole to treat Pneumocystis carinii pneumonia in patients with AIDS","volume":"328","author":"Hughes","year":"1993","journal-title":"N Engl J Med"},{"key":"10.1157\/13123842_bb0085","doi-asserted-by":"crossref","first-page":"33","DOI":"10.7326\/0003-4819-116-1-33","article-title":"Treatment of toxoplasmic encephalitis (TE) in patients with AIDS: a randomized trial comparing pyrimethamine plus clindamycin (PC) to pyrimethamine plus sulfonamides (PS)","volume":"116","author":"Dannemann","year":"1992","journal-title":"Ann Intern Med"},{"key":"10.1157\/13123842_bb0090","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1093\/clinids\/22.2.268","article-title":"Pyrimethami ne clindamycin versus pyrimethamine sulfadiazine as acute and long term therapy for toxoplasmic encephalitis in patients with AIDS","volume":"22","author":"Katlama","year":"1996","journal-title":"Clin Infect Dis"},{"key":"10.1157\/13123842_bb0095","doi-asserted-by":"crossref","first-page":"1243","DOI":"10.1086\/339551","article-title":"Randomized phase II trial of atovaquone with pyrimethamine or sulfadiazine for treatment of toxoplasmic encephalitis in patients with acquired immunodeficiency syndrome: ACTG 237\/ANRS 039 study","volume":"34","author":"Chirgwin","year":"2002","journal-title":"Clin Infect Dis"},{"key":"10.1157\/13123842_bb0100","doi-asserted-by":"crossref","first-page":"2049","DOI":"10.1128\/AAC.35.10.2049","article-title":"Pyrimethamine-clarythromycin combination for therapy of acute Toxoplasma encephalitis in patients with AIDS","volume":"35","author":"Fern\u00e1ndez-Mart\u00edn","year":"1991","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1157\/13123842_bb0105","doi-asserted-by":"crossref","first-page":"1346","DOI":"10.1128\/AAC.42.6.1346","article-title":"Randomized trial of trimethoprim-sulfamethoxazole versus pyrimethamine-sulfadiazine for therapy of toxoplasmic encephalitis in patients with AIDS. Italian Collaborative Study Group","volume":"42","author":"Torre","year":"1998","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1157\/13123842_bb0110","doi-asserted-by":"crossref","first-page":"1044","DOI":"10.1056\/NEJM198904203201604","article-title":"Treatment and prophylaxis of Isospora belli infection in patients with the acquired immunodeficiency syndrome","volume":"320","author":"Pape","year":"1989","journal-title":"N Engl J Med"},{"key":"10.1157\/13123842_bb0115","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1097\/01.qco.0000244055.46382.23","article-title":"Microsporidiosis: current status","volume":"19","author":"Didier","year":"2006","journal-title":"Curr Opin Infect Dis"},{"key":"10.1157\/13123842_bb0120","doi-asserted-by":"crossref","first-page":"1963","DOI":"10.1056\/NEJMoa012924","article-title":"Fumagillin treatment of intestinal microsporidiosis","volume":"346","author":"Molina","year":"2002","journal-title":"N Engl J Med"},{"key":"10.1157\/13123842_bb0125","doi-asserted-by":"crossref","first-page":"1373","DOI":"10.1086\/515268","article-title":"Albendazole for treatment and prophylaxis of microsporidiosis due to Encephalitozoon intestinalis in patients with AIDS: A randomized double-blind controlled trial","volume":"177","author":"Molina","year":"1998","journal-title":"J Infect Dis"},{"key":"10.1157\/13123842_bb0130","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1097\/00126334-200010010-00006","article-title":"Eradication of cryptosporidia and microsporidia following successful antiretroviral therapy","volume":"25","author":"Miao","year":"2000","journal-title":"J Acquir Immune Defic Syndr"},{"key":"10.1157\/13123842_bb0135","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1093\/infdis\/170.2.419","article-title":"Paromomycin for cryptosporidiosis in AIDS: a prospective, double blind trial","volume":"170","author":"White","year":"1994","journal-title":"J Infect Dis"},{"key":"10.1157\/13123842_bb0140","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1111\/j.1365-2125.2007.02873.x","article-title":"Treatment of cryptosporidiosis in immunocompromised individuals: Systematic review and meta-analysis","volume":"63","author":"Abubakar","year":"2007","journal-title":"Br J Clin Pharmacol"},{"key":"10.1157\/13123842_bb0145","doi-asserted-by":"crossref","first-page":"887","DOI":"10.1111\/j.1365-2036.2006.03033.x","article-title":"Nitazoxanide in the treatment of acquired immune deficiency syndrome-related cryptosporidiosis: results of the United States compassionate use program in 365 patients","volume":"24","author":"Rossignol","year":"2006","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1157\/13123842_bb0150","doi-asserted-by":"crossref","first-page":"1063","DOI":"10.1097\/00002030-199906180-00009","article-title":"Treatment of visceral leishmaniasis in HIV-infected patients: a randomized trial comparing meglumine antimoniate with amphotericin B. Spanish HIV-Leishmania Study Group","volume":"13","author":"Laguna","year":"1999","journal-title":"AIDS"},{"key":"10.1157\/13123842_bb0155","doi-asserted-by":"crossref","first-page":"938","DOI":"10.1093\/clinids\/22.6.938","article-title":"Short course treatment of visceral leishmaniasis with liposomal amphotericin B (AmBisome)","volume":"22","author":"Davidson","year":"1996","journal-title":"Clin Infect Dis"},{"key":"10.1157\/13123842_bb0160","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1093\/jac\/dkg356","article-title":"Amphotericin B lipid complex vs meglumine antimoniate in the treatment of visceral leishmaniasis in HIV-infected patients: a multicenter, open label, blinded, randomization, parallel controlled clinical trial","volume":"52","author":"Laguna","year":"2003","journal-title":"J Antimicrob Chemother"},{"key":"10.1157\/13123842_bb0165","doi-asserted-by":"crossref","first-page":"1520","DOI":"10.1086\/425359","article-title":"Oral miltefosine for leishmaniasis in immunocompromised patients: compassionate use in 39 patients with HIV infection","volume":"39","author":"Sindermann","year":"2004","journal-title":"Clin Infect Dis"},{"key":"10.1157\/13123842_bb0170","doi-asserted-by":"crossref","first-page":"2571","DOI":"10.1056\/NEJMoa066536","article-title":"Injectable paromomycinfor visceral leishmaniasis in India","volume":"356","author":"Sundar","year":"2007","journal-title":"N Engl J Med"},{"key":"10.1157\/13123842_bb0175","doi-asserted-by":"crossref","first-page":"655","DOI":"10.7326\/0003-4819-117-8-655","article-title":"Fluconazole compared with ketoconazole for the treatment of Candida esophagitis in AIDS. A randomized trial","volume":"117","author":"Laine","year":"1992","journal-title":"Ann Intern Med"},{"key":"10.1157\/13123842_bb0180","doi-asserted-by":"crossref","first-page":"613","DOI":"10.3109\/00365549509047076","article-title":"Fluconazole compared with itraconazole in the treatment of esophageal candidiasis in AIDS patients: a double-blind, randomized, controlled clinical study","volume":"27","author":"Barbaro","year":"1995","journal-title":"Scand J Infect Dis"},{"key":"10.1157\/13123842_bb0185","doi-asserted-by":"crossref","first-page":"1204","DOI":"10.1086\/513664","article-title":"Oropharyngeal candidiasis in patients with AIDS: randomized comparison of fluconazole versus nystatin oral suspensions","volume":"24","author":"Pons","year":"1997","journal-title":"Clin Infect Dis"},{"key":"10.1157\/13123842_bb0190","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1016\/S0002-9343(97)00307-0","article-title":"Randomized trial of itraconazole oral solution for oropharyngeal candidiasis in HIV\/AIDS patients","volume":"104","author":"Graybill","year":"1998","journal-title":"Am J Med"},{"key":"10.1157\/13123842_bb0195","doi-asserted-by":"crossref","first-page":"556","DOI":"10.1086\/514571","article-title":"Refractory mucosal candidiasis in patients with human immunodeficiency virus infection","volume":"26","author":"Fichtenbaum","year":"1998","journal-title":"Clin Infect Dis"},{"key":"10.1157\/13123842_bb0200","doi-asserted-by":"crossref","first-page":"903","DOI":"10.1089\/088922202760265579","article-title":"Response and relapse rates of candidal esophagitis in HIV-infected patients treated with caspofungin","volume":"18","author":"Dinubile","year":"2002","journal-title":"AIDS Res Hum Retroviruses"},{"key":"10.1157\/13123842_bb0205","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1086\/511039","article-title":"Posaconazole for the treatment of azole-refractory oropharyngeal and esophageal candidiasis in subjects with HIV infection","volume":"44","author":"Skiest","year":"2007","journal-title":"Clin Infect Dis"},{"key":"10.1157\/13123842_bb0210","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1128\/CMR.8.4.515","article-title":"Cryptococcosis in the era of AIDS \u2013 100 years after the discovery of Cryptococcus neoformans","volume":"8","author":"Mitchell","year":"1995","journal-title":"Clin Microbiol Rev"},{"key":"10.1157\/13123842_bb0215","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1097\/00005792-199307000-00001","article-title":"Catastrophic visual loss due to Cryptococcus neoformans meningitis","volume":"72","author":"Rex","year":"1993","journal-title":"Medicine (Baltimore)"},{"key":"10.1157\/13123842_bb0220","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1056\/NEJM199707033370103","article-title":"Treatment of cryptococcal meningitis associated with the acquired immunodeficiency syndrome. National Institute of Allergy and Infectious Diseases Mycoses Study Group and AIDS Clinical Trials Group","volume":"337","author":"van der Horst","year":"1997","journal-title":"N Engl J Med"},{"key":"10.1157\/13123842_bb0225","doi-asserted-by":"crossref","first-page":"1463","DOI":"10.1097\/00002030-199712000-00010","article-title":"Liposomal amphotericin B (AmBisome) compared with amphotericin B both followed by oral fluconazole in the treatment of AIDS-associated cryptococcal meningitis","volume":"11","author":"Leenders","year":"1997","journal-title":"AIDS"},{"key":"10.1157\/13123842_bb0230","doi-asserted-by":"crossref","first-page":"690","DOI":"10.1128\/AAC.36.3.690","article-title":"Use of high-dose fluconazole as salvage therapy for cryptococcal meningitis in patients with AIDS","volume":"36","author":"Berry","year":"1992","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1157\/13123842_bb0235","doi-asserted-by":"crossref","first-page":"741","DOI":"10.1093\/clinids\/19.4.741","article-title":"Fluconazole combined with flucytosine for treatment of cryptococcal meningitis in patients with AIDS","volume":"19","author":"Larsen","year":"1994","journal-title":"Clin Infect Dis"},{"key":"10.1157\/13123842_bb0240","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1056\/NEJM199201093260202","article-title":"Comparison of amphotericin B with fluconazole in the treatment of acute AIDS-associated cryptococcal meningitis. The NIAID Mycoses Study Group and the AIDS Clinical Trials Group","volume":"326","author":"Saag","year":"1992","journal-title":"N Engl J Med"},{"key":"10.1157\/13123842_bb0245","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1097\/00042560-199802010-00006","article-title":"Management of elevated intracranial pressure in patients with Cryptococcal meningitis","volume":"17","author":"Fessler","year":"1998","journal-title":"J Acquir Immune Defic Syndr Hum Retrovirol"},{"key":"10.1157\/13123842_bb0250","doi-asserted-by":"crossref","first-page":"1562","DOI":"10.1093\/infdis\/168.6.1562","article-title":"Defective antifungal activity of monocyte-derived macrophages from human immunodeficiency virus-infected children against Aspergillus fumigatus","volume":"168","author":"Roilides","year":"1993","journal-title":"J Infect Dis"},{"key":"10.1157\/13123842_bb0255","doi-asserted-by":"crossref","first-page":"654","DOI":"10.1056\/NEJM199103073241003","article-title":"Pulmonary aspergillosis in the acquired immunodeficiency syndrome","volume":"324","author":"Denning","year":"1991","journal-title":"N Engl J Med"},{"key":"10.1157\/13123842_bb0260","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1378\/chest.114.1.131","article-title":"Risk factors and outcomes associated with identification of Aspergillus in respiratory specimens from persons with HIV disease. Pulmonary Complications of HIV Infection Study Group","volume":"114","author":"Wallace","year":"1998","journal-title":"Chest"},{"key":"10.1157\/13123842_bb0265","doi-asserted-by":"crossref","first-page":"1079","DOI":"10.1164\/ajrccm.152.3.7663787","article-title":"Pathogenesis of pulmonary aspergillosis. Granulocytopenia versus cyclosporine and methylprednisolone-induced immunosuppression","volume":"152","author":"Berenguer","year":"1995","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1157\/13123842_bb0270","doi-asserted-by":"crossref","first-page":"408","DOI":"10.1056\/NEJMoa020191","article-title":"Voriconazole versus amphotericin B for primary therapy of invasive aspergillosis","volume":"347","author":"Herbrecht","year":"2002","journal-title":"N Engl J Med"},{"key":"10.1157\/13123842_bb0275","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1164\/rccm.200505-727SO","article-title":"Current approaches to diagnosis and treatment of invasive aspergillosis","volume":"173","author":"Segal","year":"2006","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1157\/13123842_bb0280","doi-asserted-by":"crossref","first-page":"696","DOI":"10.1086\/313756","article-title":"Practice guidelines for diseases caused by Aspergillus. Infectious Diseases Society of America","volume":"30","author":"Stevens","year":"2000","journal-title":"Clin Infect Dis"},{"key":"10.1157\/13123842_bb0285","first-page":"1","article-title":"Treating opportunistic infections among HIV-infected adults and adolescents: recommendations from CDC, the National Institutes of Health, and the HIV Medicine Association\/Infectious Diseases Society of America","volume":"53","author":"Benson","year":"2004","journal-title":"MMWR Recomm Rep"},{"key":"10.1157\/13123842_bb0290","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1016\/0738-081X(91)90120-A","article-title":"Herpes virus infections and HIV disease","volume":"9","author":"Berger","year":"1991","journal-title":"Clin Dermatol"},{"key":"10.1157\/13123842_bb0295","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1097\/01.aids.0000198081.09337.a7","article-title":"Herpes simplex virus 2 infection increases HIV acquisition in men and women: systematic review and meta-analysis of longitudinal studies","volume":"20","author":"Freeman","year":"2006","journal-title":"AIDS"},{"key":"10.1157\/13123842_bb0300","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1097\/00007435-199709000-00007","article-title":"Valaciclovir versus acyclovir in the treatment of first-episode genital herpes infection. Results of an international, multicenter, double-blind, randomized clinical trial. The Valaciclovir International Herpes Simplex Virus Study Group","volume":"24","author":"Fife","year":"1997","journal-title":"Sex Transm Dis"},{"key":"10.1157\/13123842_bb0305","doi-asserted-by":"crossref","first-page":"1211","DOI":"10.1097\/00002030-200006160-00019","article-title":"Efficacy and safety of famciclovir for treating mucocutaneous herpes simplex infection in HIV-infected individuals. Collaborative Famciclovir HIV Study Group","volume":"14","author":"Romanowski","year":"2000","journal-title":"AIDS"},{"key":"10.1157\/13123842_bb0310","doi-asserted-by":"crossref","first-page":"790","DOI":"10.1056\/NEJMoa062607","article-title":"Reduction of HIV-1 RNA levels with therapy to suppress herpes simplex virus","volume":"356","author":"Nagot","year":"2007","journal-title":"N Engl J Med"},{"key":"10.1157\/13123842_bb0315","doi-asserted-by":"crossref","first-page":"1009","DOI":"10.1086\/378416","article-title":"Valacyclovir for the suppression of recurrent genital herpes in human immunodeficiency virus-infected subjects","volume":"188","author":"DeJesus","year":"2003","journal-title":"J Infect Dis"},{"key":"10.1157\/13123842_bb0320","doi-asserted-by":"crossref","first-page":"887","DOI":"10.1001\/jama.280.10.887","article-title":"Oral famciclovir for the suppression of recurrent genital herpes: a randomized controlled trial. Collaborative Famciclovir Genital Herpes Research Group","volume":"280","author":"Diaz-Mitoma","year":"1998","journal-title":"JAMA"},{"key":"10.1157\/13123842_bb0325","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1001\/jama.1988.03410020067030","article-title":"Long-term acyclovir suppression of frequently recurring genital herpes simplex virus infection. A multicenter double-blind trial","volume":"260","author":"Mertz","year":"1988","journal-title":"JAMA"},{"key":"10.1157\/13123842_bb0330","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1001\/archinte.1997.00440240109016","article-title":"Oral famciclovir for suppression of recurrent genital herpes simplex virus infection in women. A multicenter, double-blind, placebo-controlled trial. Collaborative Famciclovir Genital Herpes Research Group","volume":"157","author":"Mertz","year":"1997","journal-title":"Arch Intern Med"},{"key":"10.1157\/13123842_bb0335","doi-asserted-by":"crossref","first-page":"21","DOI":"10.7326\/0003-4819-128-1-199801010-00004","article-title":"Famciclovir for the suppression of symptomatic and asymptomatic herpes simplex virus reactivation in HIV-infected persons. A double-blind, placebocontrolled trial","volume":"128","author":"Schacker","year":"1998","journal-title":"Ann Intern Med"},{"issue":"Suppl 5","key":"10.1157\/13123842_bb0340","doi-asserted-by":"crossref","first-page":"S258","DOI":"10.1086\/422362","article-title":"Efficacy and safety of valacyclovir for the suppression and episodic treatment of herpes simplex virus in patients with HIV","volume":"39","author":"Warren","year":"2004","journal-title":"Clin Infect Dis"},{"key":"10.1157\/13123842_bb0345","doi-asserted-by":"crossref","first-page":"155","DOI":"10.2165\/00003495-200767020-00001","article-title":"Clinical and therapeutic issues for herpes simplex virus-2 and HIV co-infection","volume":"67","author":"Lingappa","year":"2007","journal-title":"Drugs"},{"key":"10.1157\/13123842_bb0350","doi-asserted-by":"crossref","first-page":"1048","DOI":"10.1136\/bmj.39189.504306.55","article-title":"Genital herpes and its management","volume":"334","author":"Sen","year":"2007","journal-title":"BMJ"},{"key":"10.1157\/13123842_bb0355","doi-asserted-by":"crossref","first-page":"1255","DOI":"10.1056\/NEJM199904223401608","article-title":"Antiviral drugs","volume":"340","author":"Balfour","year":"1999","journal-title":"N Engl J Med"},{"key":"10.1157\/13123842_bb0360","first-page":"254","article-title":"Management of acyclovir-resistant herpes simplex and varicella-zoster virus infections","volume":"7","author":"Balfour","year":"1994","journal-title":"J Acquir Immune Defic Syndr"},{"key":"10.1157\/13123842_bb0365","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1128\/JCM.42.1.242-249.2004","article-title":"Surveillance network for herpes simplex virus resistance to antiviral drugs: 3-year follow-up","volume":"42","author":"Danve-Szatanek","year":"2004","journal-title":"J Clin Microbiol"},{"key":"10.1157\/13123842_bb0370","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1016\/S0166-3542(87)80004-9","article-title":"Antiviral activity of phosphonylmethoxyalkyl derivatives of purine and pyrimidines","volume":"8","author":"De","year":"1987","journal-title":"Antiviral Res"},{"issue":"Suppl 1","key":"10.1157\/13123842_bb0375","doi-asserted-by":"crossref","first-page":"S1","DOI":"10.1086\/510206","article-title":"Recommendations for the management of herpes zoster","volume":"44","author":"Dworkin","year":"2007","journal-title":"Clin Infect Dis"},{"key":"10.1157\/13123842_bb0380","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1016\/j.ophtha.2006.06.058","article-title":"Treatment of acute retinal necrosis syndrome with oral antiviral medications","volume":"114","author":"Aizman","year":"2007","journal-title":"Ophthalmology"},{"key":"10.1157\/13123842_bb0385","doi-asserted-by":"crossref","first-page":"756","DOI":"10.1016\/j.ophtha.2006.08.037","article-title":"Acute retinal necrosis features, management, and outcomes","volume":"114","author":"Lau","year":"2007","journal-title":"Ophthalmology"},{"key":"10.1157\/13123842_bb0390","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1016\/S0953-4431(00)00052-7","article-title":"Progressive outer retinal necrosis syndrome: a comprehensive review of its clinical presentation, relationship to immune system status, and management","volume":"12","author":"Austin","year":"2000","journal-title":"Clin Eye Vis Care"},{"key":"10.1157\/13123842_bb0395","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1016\/j.jcv.2006.12.012","article-title":"Progressive outer retinal necrosis in the era of highly active antiretroviral therapy: successful management with intravitreal injections and monitoring with quantitative PCR","volume":"38","author":"Yin","year":"2007","journal-title":"J Clin Virol"},{"key":"10.1157\/13123842_bb0400","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1016\/S0002-9394(01)01322-8","article-title":"Characteristics of patients with cytomegalovirus retinitis in the era of highly active antiretroviral therapy","volume":"133","author":"Jabs","year":"2002","journal-title":"Am J Ophthalmol"},{"key":"10.1157\/13123842_bb0405","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1093\/infdis\/168.3.557","article-title":"A randomized, controlled study of intravenous ganciclovir therapy for cytomegalovirus peripheral retinitis in patients with AIDS. AIDS Clinical Trials Group and Cytomegalovirus Cooperative Study Group","volume":"168","author":"Spector","year":"1993","journal-title":"J Infect Dis"},{"key":"10.1157\/13123842_bb0410","doi-asserted-by":"crossref","first-page":"665","DOI":"10.7326\/0003-4819-115-9-665","article-title":"A randomized, controlled trial of foscarnet in the treatment of cytomegalovirus retinitis in patients with AIDS","volume":"115","author":"Palestine","year":"1991","journal-title":"Ann Intern Med"},{"key":"10.1157\/13123842_bb0415","doi-asserted-by":"crossref","first-page":"257","DOI":"10.7326\/0003-4819-126-4-199702150-00001","article-title":"Intravenous cidofovir for peripheral cytomegalovirus retinitis in patients with AIDS. A randomized, controlled trial","volume":"126","author":"Lalezari","year":"1997","journal-title":"Ann Intern Med"},{"key":"10.1157\/13123842_bb0420","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1056\/NEJM199509073331002","article-title":"Oral ganciclovir as maintenance treatment for cytomegalovirus retinitis in patients with AIDS. Syntex Cooperative Oral Ganciclovir Study Group","volume":"333","author":"Drew","year":"1995","journal-title":"N Engl J Med"},{"key":"10.1157\/13123842_bb0425","doi-asserted-by":"crossref","first-page":"1063","DOI":"10.1056\/NEJM199904083401402","article-title":"Oral ganciclovir for patients with cytomegalovirus retinitis treated with a ganciclovir implant. Roche Ganciclovir Study Group","volume":"340","author":"Martin","year":"1999","journal-title":"N Engl J Med"},{"key":"10.1157\/13123842_bb0430","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1056\/NEJM199707103370203","article-title":"Treatment of cytomegalovirus retinitis with a sustained-release ganciclovir implant. The Ganciclovir Implant Study Group","volume":"337","author":"Musch","year":"1997","journal-title":"N Engl J Med"},{"key":"10.1157\/13123842_bb0435","doi-asserted-by":"crossref","first-page":"1119","DOI":"10.1056\/NEJMoa011759","article-title":"A controlled trial of valganciclovir as induction therapy for cytomegalovirus retinitis","volume":"346","author":"Martin","year":"2002","journal-title":"N Engl J Med"},{"key":"10.1157\/13123842_bb0440","doi-asserted-by":"crossref","first-page":"1001","DOI":"10.1086\/512368","article-title":"Change over time in incidence of ganciclovir resistance in patients with cytomegalovirus retinitis","volume":"44","author":"Martin","year":"2007","journal-title":"Clin Infect Dis"},{"key":"10.1157\/13123842_bb0445","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1097\/00042560-199804010-00008","article-title":"Randomized, controlled study of the safety and efficacy of intravenous cidofovir for the treatment of relapsing cytomegalovirus retinitis in patients with AIDS","volume":"17","author":"Lalezari","year":"1998","journal-title":"J Acquir Immune Defic Syndr Hum Retrovirol"},{"key":"10.1157\/13123842_bb0450","doi-asserted-by":"crossref","first-page":"1791","DOI":"10.1097\/00002030-200209060-00012","article-title":"A pilot study of cidofovir for progressive multifocal leukoencephalopathy in AIDS","volume":"16","author":"Marra","year":"2002","journal-title":"AIDS"},{"issue":"Suppl A","key":"10.1157\/13123842_bb0455","first-page":"S157","article-title":"Altered natural history of AIDS-related opportunistic infections in the era of potent combination antiretroviral therapy","volume":"12","author":"Jacobson","year":"1998","journal-title":"AIDS"},{"key":"10.1157\/13123842_bb0460","doi-asserted-by":"crossref","first-page":"2467","DOI":"10.1097\/00002030-199818000-00016","article-title":"Treatment of AIDS-associated progressive multifocal leukoencephalopathy with highly active antiretroviral therapy","volume":"12","author":"Miralles","year":"1998","journal-title":"AIDS"},{"key":"10.1157\/13123842_bb0465","doi-asserted-by":"crossref","first-page":"1152","DOI":"10.1086\/514762","article-title":"Progressive multifocal leukoencephalopathy in patients with AIDS receiving highly active antiretroviral therapy","volume":"28","author":"Tantisiriwat","year":"1999","journal-title":"Clin Infect Dis"},{"key":"10.1157\/13123842_bb0470","doi-asserted-by":"crossref","first-page":"1047","DOI":"10.1086\/374048","article-title":"Clinical course and prognostic factors of progressive multifocal leukoencephalopathy in patients treated with highly active antiretroviral therapy","volume":"36","author":"Berenguer","year":"2003","journal-title":"Clin Infect Dis"},{"key":"10.1157\/13123842_bb0475","doi-asserted-by":"crossref","first-page":"1900","DOI":"10.1097\/00002030-200109280-00028","article-title":"Inflammatory reactions in progressive multifocal leukoencephalopathy after highly active antiretroviral therapy","volume":"15","author":"Miralles","year":"2001","journal-title":"AIDS"},{"key":"10.1157\/13123842_bb0480","doi-asserted-by":"crossref","first-page":"1692","DOI":"10.1212\/01.wnl.0000242728.26433.12","article-title":"Immune reconstitution inflammatory syndrome associated with PML in AIDS: a treatable disorder","volume":"67","author":"Mart\u00ednez","year":"2006","journal-title":"Neurology"},{"issue":"Suppl 1","key":"10.1157\/13123842_bb0485","doi-asserted-by":"crossref","first-page":"S1","DOI":"10.1086\/518667","article-title":"Tuberculosis and HIV coinfection: current state of knowledge and research priorities","volume":"196","author":"Friedland","year":"2007","journal-title":"J Infect Dis"},{"key":"10.1157\/13123842_bb0490","first-page":"1","volume":"52","author":"Treatment of tuberculosis","year":"2003","journal-title":"MMWR Recomm Rep"},{"key":"10.1157\/13123842_bb0495","doi-asserted-by":"crossref","first-page":"749","DOI":"10.1016\/S0025-7753(00)71680-0","volume":"115","author":"Consensus statement on directly observed therapies for tuberculosis","year":"2000","journal-title":"Med Clin (Barc)"},{"key":"10.1157\/13123842_bb0500","doi-asserted-by":"crossref","first-page":"1199","DOI":"10.1164\/rccm.200509-1529OC","article-title":"Treatment outcomes of patients with HIV and tuberculosis","volume":"175","author":"Nahid","year":"2007","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1157\/13123842_bb0505","first-page":"1","article-title":"Treating opportunistic infections among HIV-exposed and infected children: recommendations from CDC, the National Institutes of Health, and the Infectious Diseases Society of America","volume":"53","author":"Mofenson","year":"2004","journal-title":"MMWR Recomm Rep"},{"key":"10.1157\/13123842_bb0510","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1157\/13096750","volume":"25","author":"Recommendations from the GESIDA\/Spanish AIDS Plan regarding antiretroviral treatment in adults with human immunodeficiency virus infection (update January 2007)","year":"2007","journal-title":"Enferm Infecc Microbiol Clin"},{"key":"10.1157\/13123842_bb0515","unstructured":"\u201cDear Health Care Provider letter-Roche pharmaceuticals (7-2-2005); 2005\u201d 2005."},{"key":"10.1157\/13123842_bb0520","doi-asserted-by":"crossref","first-page":"1017","DOI":"10.1093\/jac\/dkl357","article-title":"Efavirenz trough levels are not associated with virological failure throughout therapy with 800 mg daily and a rifampicin-containing antituberculosis regimen","volume":"58","author":"L\u00f3pez-Cort\u00e9s","year":"2006","journal-title":"J Antimicrob Chemother"},{"key":"10.1157\/13123842_bb0525","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1097\/QAD.0b013e328011efac","article-title":"Tuberculosis-associated immune reconstitution disease: incidence, risk factors and impact in an antiretroviral treatment service in South Africa","volume":"21","author":"Lawn","year":"2007","journal-title":"AIDS"},{"key":"10.1157\/13123842_bb0530","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1097\/01.qai.0000230521.86964.86","article-title":"Survival rate and risk factors of mortality among HIV\/tuberculosis-coinfected patients with and without antiretroviral therapy","volume":"43","author":"Manosuthi","year":"2006","journal-title":"J Acquir Immune Defic Syndr"},{"key":"10.1157\/13123842_bb0535","doi-asserted-by":"crossref","first-page":"791","DOI":"10.1136\/thx.2006.058867","article-title":"Adverse events and treatment interruption in tuberculosis patients with and without HIV co-infection","volume":"61","author":"Breen","year":"2006","journal-title":"Thorax"},{"key":"10.1157\/13123842_bb0540","first-page":"1176","volume":"55","author":"Centers for Disease Control and Prevention; Revised definition of extensively drug-resistant tuberculosis","year":"2006","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"10.1157\/13123842_bb0545","doi-asserted-by":"crossref","first-page":"1234","DOI":"10.1086\/378807","article-title":"A prospective, randomized trial examining the efficacy and safety of clarithromycin in combination with ethambutol, rifabutin, or both for the treatment of disseminated Mycobacterium avium complex disease in persons with acquired immunodeficiency syndrome","volume":"37","author":"Benson","year":"2003","journal-title":"Clin Infect Dis"},{"key":"10.1157\/13123842_bb0550","doi-asserted-by":"crossref","first-page":"845","DOI":"10.1056\/NEJM199509283331305","article-title":"Bacterial pneumonia in persons infected with the human immunodeficiency virus. The Pulmonary Complications of HIV Infection Study Group","volume":"333","author":"Hirschtick","year":"1995","journal-title":"N Engl J Med"},{"key":"10.1157\/13123842_bb0555","doi-asserted-by":"crossref","first-page":"1364","DOI":"10.1086\/339882","article-title":"Recurrent invasive pneumococcal disease in individuals with human immunodeficiency virus infection","volume":"185","author":"Mcellistrem","year":"2002","journal-title":"J Infect Dis"},{"key":"10.1157\/13123842_bb0560","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1097\/00002030-200201040-00011","article-title":"Prospective study of etiologic agents of community-acquired pneumonia in patients with HIV infection","volume":"16","author":"Rimland","year":"2002","journal-title":"AIDS"},{"key":"10.1157\/13123842_bb0565","doi-asserted-by":"crossref","first-page":"1533","DOI":"10.1001\/archinte.165.13.1533","article-title":"Epidemiologic changes in bacteremic pneumococcal disease in patients with HIV in the era of highly actived antiretroviral therapy","volume":"165","author":"Grau","year":"2005","journal-title":"Arch Intern Med"},{"key":"10.1157\/13123842_bb0570","doi-asserted-by":"crossref","first-page":"3350","DOI":"10.1001\/jama.1992.03490230080032","article-title":"Invasive Haemophilys influenzae infections in men with HIV infection","volume":"268","author":"Steinhart","year":"1992","journal-title":"JAMA"},{"key":"10.1157\/13123842_bb0575","first-page":"823","article-title":"Serious Pseudomonas aeruginosa infection in AIDS","volume":"7","author":"Shepp","year":"1994","journal-title":"J Acquir Immune Defic Syndr"},{"key":"10.1157\/13123842_bb0580","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1086\/313954","article-title":"Practice Guidelines for the management of community-acquired pneumonia in adults","volume":"31","author":"Barlett","year":"2000","journal-title":"Clin Infect Dis"},{"key":"10.1157\/13123842_bb0585","doi-asserted-by":"crossref","first-page":"1399","DOI":"10.1001\/archinte.160.10.1399","article-title":"Management of community-acquired pneumonia in the era of pneumococcal resistence: a report from the Drug-Resistant Streptococcus pneumoniae Therapeutic Working Group","volume":"160","author":"Heffelfinger","year":"2000","journal-title":"Arch Intern Med"},{"key":"10.1157\/13123842_bb0590","first-page":"1","article-title":"Update on management of patients with Noacardia infection","volume":"17","author":"Threlkeld","year":"1997","journal-title":"Curr Clin Topics Infect Dis"},{"key":"10.1157\/13123842_bb0595","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1016\/0163-4453(92)92746-6","article-title":"Rhodococcus equi infection in patients with AIDS","volume":"24","author":"Drancourt","year":"1992","journal-title":"J Infect"},{"key":"10.1157\/13123842_bb0600","first-page":"380","article-title":"Rhodococcus equi infection in HIV-positive patients: Report of 5 cases and literature overview","volume":"49","author":"Fiaccadori","year":"1994","journal-title":"Arch Chest Dis"},{"issue":"Suppl 1","key":"10.1157\/13123842_bb0605","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1093\/clinids\/21.Supplement_1.S84","article-title":"Bacterial enteric infections in persons infected with human immunodeficiency virus","volume":"21","author":"Angulo","year":"1995","journal-title":"Clin Infect Dis"},{"key":"10.1157\/13123842_bb0610","doi-asserted-by":"crossref","first-page":"1495","DOI":"10.1097\/00002030-199212000-00012","article-title":"Salmonella, Campylobacter and Shigella in HIV-seropositive patients","volume":"6","author":"Nelson","year":"1992","journal-title":"AIDS"},{"key":"10.1157\/13123842_bb0615","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1086\/318514","article-title":"Practice guidelines for the management of infections diarrhea","volume":"32","author":"Guerrant","year":"2001","journal-title":"Clin Infect Dis"},{"key":"10.1157\/13123842_bb0620","doi-asserted-by":"crossref","first-page":"951","DOI":"10.1086\/515248","article-title":"Development of quinolone-resistant Campylobacter fetus bacteriemia in human immunodeficiency virus-infected patients","volume":"177","author":"Meier","year":"1998","journal-title":"J Infect Dis"},{"key":"10.1157\/13123842_bb0625","doi-asserted-by":"crossref","first-page":"820","DOI":"10.3201\/eid0506.990614","article-title":"HIV infection as a risk factor for shigellosis","volume":"5","author":"Baer","year":"1999","journal-title":"Emerg Infect Dis"},{"key":"10.1157\/13123842_bb0630","doi-asserted-by":"crossref","first-page":"411","DOI":"10.3109\/00365549409008614","article-title":"Polymicrobial and recurrent bacteriemia with Shigella in a patient with AIDS","volume":"26","author":"Kristjansson","year":"1994","journal-title":"Scand J Infect Dis"},{"key":"10.1157\/13123842_bb0635","doi-asserted-by":"crossref","first-page":"1647","DOI":"10.1128\/AAC.46.6.1647-1650.2002","article-title":"Reassessment of Clostridium difficile susceptibility to metronidazole and vancomycin","volume":"46","author":"Pel\u00e1ez","year":"2002","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1157\/13123842_bb0640","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1097\/00007435-200001000-00011","article-title":"HIV prevalence in patients with syphilis, United States","volume":"27","author":"Blocker","year":"2000","journal-title":"Sex Transm Dis"},{"issue":"2 Pt2","key":"10.1157\/13123842_bb0645","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1016\/S0190-9622(88)70062-6","article-title":"Unusual manifestations of secondary syphilis and abnormal humoral immune response to Treponema pallidum antigens in a homosexual man with asymptomatic human immunodeficiency virus infection","volume":"18","author":"Radolf","year":"1988","journal-title":"J Am Acad Dermatol"},{"key":"10.1157\/13123842_bb0650","unstructured":"Centers for Disease Control and Prevention. Sexually Transmitted Disease Surveillance, 2004. Atlanta GA: US Department of Health and Human Services; 2005."},{"key":"10.1157\/13123842_bb0655","doi-asserted-by":"crossref","first-page":"1510","DOI":"10.1001\/jama.290.11.1510","article-title":"Update on syphilis: resurgence of an old problem","volume":"290","author":"Golden","year":"2003","journal-title":"JAMA"},{"key":"10.1157\/13123842_bb0660","doi-asserted-by":"crossref","first-page":"1469","DOI":"10.1056\/NEJM199412013312201","article-title":"The response of syntomatic neurosyphilis to high-dose intravenous penicillin G in patients with human immunodeficiency virus infection","volume":"331","author":"Gordon","year":"1994","journal-title":"N Engl J Med"},{"key":"10.1157\/13123842_bb0665","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1056\/NEJM199707313370504","article-title":"A randomized trial of enhanced therapy for early syphilis in patients with or without human immunodeficiency virus infection","volume":"337","author":"Rolfs","year":"1997","journal-title":"N Engl J Med"},{"key":"10.1157\/13123842_bb0670","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1086\/375586","article-title":"Prevalence of Bartonella infection among human immunodeficiency virus infected patients with fever","volume":"37","author":"Koehler","year":"2003","journal-title":"Clin Infect Dis"},{"key":"10.1157\/13123842_bb0675","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1093\/clinids\/13.3.413","article-title":"Listeria monocytogenes infections in patients with AIDS: Report of five cases and review","volume":"13","author":"Decker","year":"1991","journal-title":"Rev Infect Dis"},{"key":"10.1157\/13123842_bb0680","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1016\/S0163-4453(96)92929-1","article-title":"Is Amoxicillin-Cotrimoxazole the most appropiate antibiotic regimen for Listeria meningoencephalitis? Review of 22 cases and the literature","volume":"33","author":"Merle-Melet","year":"1996","journal-title":"J Infect"},{"key":"10.1157\/13123842_bb0685","doi-asserted-by":"crossref","first-page":"1859","DOI":"10.1016\/j.clinthera.2005.12.012","article-title":"Tinidazole: a nitroimidazole antiprotozoal agent","volume":"27","author":"Fung","year":"2005","journal-title":"Clin Ther"},{"key":"10.1157\/13123842_bb0690","doi-asserted-by":"crossref","first-page":"195","DOI":"10.3109\/00365548409087141","article-title":"long-term follow up study of amoebiasis treated with metronidazole","volume":"16","author":"Pehrson","year":"1984","journal-title":"Scand J Infect Dis"},{"issue":"Suppl","key":"10.1157\/13123842_bb0695","first-page":"1","volume":"5","author":"Drug for parasitic infections","year":"2007","journal-title":"The Medical Letter"},{"key":"10.1157\/13123842_bb0700","first-page":"366","article-title":"Amebic peritonitis","volume":"66","author":"Monga","year":"1976","journal-title":"Am J Gastroenterol"},{"key":"10.1157\/13123842_bb0705","doi-asserted-by":"crossref","first-page":"1030","DOI":"10.1046\/j.1360-2276.2003.01130.x","article-title":"Treatment of amoebic liver abscess with metronidazole alone or in combination with ultrasound-guided needle aspiration: a comparative, prospective and randomized study","volume":"8","author":"Blessmann","year":"2003","journal-title":"Trop Med Int Health"},{"key":"10.1157\/13123842_bb0710","doi-asserted-by":"crossref","first-page":"995","DOI":"10.1097\/01.aids.0000174445.40379.e0","article-title":"The potential for interactions between antimalarial and antiretroviral drugs","volume":"19","author":"Khoo","year":"2005","journal-title":"AIDS"},{"key":"10.1157\/13123842_bb0715","article-title":"Other parasitic infections, Management of the HIV-infected patient","author":"Cahn","year":"2002","journal-title":"Martin Dunitz Editors UK"},{"key":"10.1157\/13123842_bb0720","doi-asserted-by":"crossref","first-page":"1407","DOI":"10.1016\/S0140-6736(96)04128-1","article-title":"Randomised trial of efficacy of benznidazole in treatment of early Trypanosoma cruzi infection","volume":"348","author":"De Andrade","year":"1996","journal-title":"Lancet"},{"key":"10.1157\/13123842_bb0725","doi-asserted-by":"crossref","first-page":"280","DOI":"10.4269\/ajtmh.1986.35.280","article-title":"In vitro and in vivo effects of itraconazole against Trypanosoma cruzi","volume":"35","author":"McCabe","year":"1986","journal-title":"Am J Trop Med Hyg"},{"key":"10.1157\/13123842_bb0730","unstructured":"World Health Organization: Control and surveillance of African Trypanosomiasis. WHO Technical Report Series No 881. Geneva. 1998."},{"key":"10.1157\/13123842_bb0735","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1016\/j.trstmh.2005.03.017","article-title":"Randomized controlled trial of three regimens of melarsoprol in the treatment of Trypanosoma brucei gambiense trypanosomiasis","volume":"100","author":"Pepin","year":"2006","journal-title":"Transactions of the Royal Society of Tropical Medicine and Hygiene"},{"key":"10.1157\/13123842_bb0740","doi-asserted-by":"crossref","first-page":"1246","DOI":"10.1016\/S0140-6736(89)92340-4","article-title":"Trial of prednisolone for prevention of melarsoprol-induced encephalopathy in gambiense sleeping sickness","volume":"1","author":"Pepin","year":"1989","journal-title":"Lancet"},{"key":"10.1157\/13123842_bb0745","doi-asserted-by":"crossref","first-page":"654","DOI":"10.7326\/0003-4819-121-9-199411010-00004","article-title":"Cyclospora infection in adults infected with HIV: Clinical manifestations, treatment, and prophylaxis","volume":"121","author":"Pape","year":"1994","journal-title":"Ann Intern Med"},{"key":"10.1157\/13123842_bb0750","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1128\/CMR.17.1.208-217.2004","article-title":"Strongyloides stercoralis in the Immunocompromised Population","volume":"17","author":"Keiser","year":"2004","journal-title":"Clin Microbiol Rev"},{"issue":"Suppl 3","key":"10.1157\/13123842_bb0755","first-page":"32","article-title":"Randomized comparative trial of two high-dose albendazole regimens for uncomplicated human strongyloidiasis","volume":"37","author":"Singthong","year":"2006","journal-title":"Southeast Asian J Trop Med Public Health"},{"key":"10.1157\/13123842_bb0760","doi-asserted-by":"crossref","first-page":"477","DOI":"10.4269\/ajtmh.1996.55.477","article-title":"A comparative trial of a single-dose ivermectin versus three days of albendazole for treatment of strongyloides stercoralis and other soil-transmitted helminth infections in children","volume":"55","author":"Marti","year":"1996","journal-title":"Am J Trop Med Hyg"},{"key":"10.1157\/13123842_bb0765","doi-asserted-by":"crossref","first-page":"814","DOI":"10.4269\/ajtmh.2006.74.814","article-title":"Efficay of paziquantel during the incubation and invasive phase of Schistosoma haematobium schistosomiasis in 18 travelers","volume":"74","author":"Grandiere-P\u00e9rez","year":"2006","journal-title":"Am J Trop Med Hyg"},{"key":"10.1157\/13123842_bb0770","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1056\/NEJMoa031294","article-title":"A trial of antiparasitic treatment to reduce the rate of seizures due to cerebral cysticercosis","volume":"350","author":"Garc\u00eda","year":"2004","journal-title":"N Engl J Med"},{"key":"10.1157\/13123842_bb0775","doi-asserted-by":"crossref","first-page":"43","DOI":"10.7326\/0003-4819-145-1-200607040-00009","article-title":"Meta-analysis: Cysticidal drugs for neurocysticercosis: albendazole and praziquantel","volume":"145","author":"Del Brutto","year":"2006","journal-title":"Ann Intern Med"},{"key":"10.1157\/13123842_bb0780","doi-asserted-by":"crossref","first-page":"436","DOI":"10.1212\/01.wnl.0000195887.63124.dc","article-title":"Albendazole trial at 15 or 30 mg\/kg\/day for subarachnoid and intraventricular cysticercosis","volume":"66","author":"G\u00f3ngora-Rivera","year":"2006","journal-title":"Neurology"},{"key":"10.1157\/13123842_bb0785","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1086\/509325","article-title":"Recent updates on onchocerciasis: diagnosis and treatment","volume":"44","author":"Udall","year":"2007","journal-title":"Clin Infect Dis"},{"key":"10.1157\/13123842_bb0790","doi-asserted-by":"crossref","first-page":"604","DOI":"10.1093\/infdis\/169.3.604","article-title":"Effectiveness of diethylcarbamazine in treating loiasis acquired by expatriate visitors to endemic regions: long-term follow-up","volume":"169","author":"Klion","year":"1994","journal-title":"J Infect Dis"},{"key":"10.1157\/13123842_bb0795","doi-asserted-by":"crossref","first-page":"442","DOI":"10.1016\/0140-6736(93)92859-R","article-title":"Reduction of microfilaraemia with single high-dose of ivermectin in loiasis","volume":"342","author":"Martin-Prevel","year":"1993","journal-title":"Lancet"},{"key":"10.1157\/13123842_bb0800","doi-asserted-by":"crossref","first-page":"211","DOI":"10.4269\/ajtmh.2004.71.211","article-title":"Human loiasis in a Cameroonian village: a double-blind, placebo-controlled, crossover clinical trial of a three-day albendazole regimen","volume":"71","author":"Tabi","year":"2004","journal-title":"Am J Trop Med Hyg"},{"key":"10.1157\/13123842_bb0805","doi-asserted-by":"crossref","first-page":"2116","DOI":"10.1016\/S0140-6736(05)66591-9","article-title":"Macrofilaricidal activity after doxycycline treatment of Wuchereria bancrofti: a double-blind, randomised placebo-controlled trial","volume":"365","author":"Taylor","year":"2005","journal-title":"Lancet"},{"key":"10.1157\/13123842_bb0810","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1016\/S0035-9203(97)90232-7","article-title":"Albendazole for the treatment of Mansonella perstans filariasis","volume":"91","author":"Lipani","year":"1997","journal-title":"Trans R Soc Trop Med Hyg"},{"key":"10.1157\/13123842_bb0815","first-page":"231","article-title":"Ivermectin treatment of mansonellosis in Trinidad","volume":"48","author":"Gonz\u00e1lez","year":"1999","journal-title":"West Indian Med J"},{"issue":"Suppl 1","key":"10.1157\/13123842_bb0820","doi-asserted-by":"crossref","first-page":"S9","DOI":"10.1097\/01.qai.0000286599.38431.ef","article-title":"Optimal timing and best antiretroviral regimen in treatment-naive HIV-infected individuals with advanced disease","volume":"46","author":"Manzardo","year":"2007","journal-title":"J Acquir Immune Defic Syndr"},{"key":"10.1157\/13123842_bb0825","doi-asserted-by":"crossref","first-page":"191","DOI":"10.2165\/00003495-200868020-00004","article-title":"Immune reconstitution inflammatory syndrome in HIV-infected patients receiving antiretroviral therapy: Pathogenesis, clinical manifestations and management","volume":"68","author":"Dhasmana","year":"2008","journal-title":"Drugs"},{"key":"10.1157\/13123842_bb0830","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1186\/1742-6405-4-9","article-title":"Immune reconstitution inflammatory syndrome (IRIS): Review of common infectious manifestations and treatment options","volume":"4","author":"Murdoch","year":"2007","journal-title":"AIDS Res Ther"},{"key":"10.1157\/13123842_bb0835","unstructured":"Zolopa A, Andersen J, Komarow L, S\u00e1nchez A, Suckow C, Sanne I, et al. Immediate vs deferred ART in the setting of acute AIDS-related opportunistic infection: Final results of a randomized strategy trial, ACTG A5164.15th Conference on Retroviruses and Opportunistic Infections, Boston MA, USA, February 3-6. 2008; Abstract P142."},{"key":"10.1157\/13123842_bb0840","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1016\/S0140-6736(02)09411-4","article-title":"Prognosis of HIV-1-infected patients starting highly active antiretroviral therapy: a collaborative analysis of prospective studies","volume":"360","author":"Egger","year":"2002","journal-title":"Lancet"},{"key":"10.1157\/13123842_bb0845","doi-asserted-by":"crossref","first-page":"1615","DOI":"10.1097\/01.aids.0000131375.21070.06","article-title":"Immune restoration disease after antiretroviral therapy","volume":"18","author":"French","year":"2004","journal-title":"AIDS"},{"key":"10.1157\/13123842_bb0850","first-page":"6","article-title":"Illness of Immune Reconstitution: Recognition and Management","author":"Gardner","year":"2004","journal-title":"Curr Infect Dis Rep"},{"key":"10.1157\/13123842_bb0855","first-page":"67","article-title":"The immune reconstitution inflammatory syndrome","volume":"5","author":"Shelburne","year":"2003","journal-title":"AIDS Rev"},{"key":"10.1157\/13123842_bb0860","doi-asserted-by":"crossref","first-page":"1426","DOI":"10.1097\/00002030-199907300-00032","article-title":"Contrast-enhancing progressive multifocal leukoencephalopathy as an immune reconstitution event in AIDS patients","volume":"13","author":"Collazos","year":"1999","journal-title":"AIDS"},{"key":"10.1157\/13123842_bb0865","doi-asserted-by":"crossref","first-page":"1163","DOI":"10.1097\/00002030-200006160-00013","article-title":"Changes in the natural history of cytomegalovirus retinitis following the introduction of highly active antiretroviral therapy","volume":"14","author":"Deayton","year":"2000","journal-title":"AIDS"},{"key":"10.1157\/13123842_bb0870","doi-asserted-by":"crossref","first-page":"e128","DOI":"10.1086\/344467","article-title":"Immune reconstitution cryptococcosis after initiation of successful highly active antiretroviral therapy","volume":"35","author":"Jenny-Avital","year":"2002","journal-title":"Clin Infect Dis"},{"key":"10.1157\/13123842_bb0875","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1016\/S1473-3099(05)70140-7","article-title":"Immune reconstitution disease associated with mycobacterial infections in HIV-infected individuals receiving antiretrovirals","volume":"5","author":"Lawn","year":"2005","journal-title":"Lancet Infect Dis"},{"key":"10.1157\/13123842_bb0880","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1086\/341084","article-title":"Incidence of and risk factors for severe hepatotoxicity associated with antiretroviral combination therapy","volume":"186","author":"Wit","year":"2002","journal-title":"J Infect Dis"},{"key":"10.1157\/13123842_bb0885","doi-asserted-by":"crossref","first-page":"482","DOI":"10.1097\/QCO.0b013e3282a6463d","article-title":"Immune reconstitution disease associated with parasitic infections following initiation of antiretroviral therapy","volume":"20","author":"Lawn","year":"2007","journal-title":"Curr Opin Infect Dis"},{"key":"10.1157\/13123842_bb0890","doi-asserted-by":"crossref","first-page":"1417","DOI":"10.1080\/1042819031000083280","article-title":"Immune reconstitution inflammatory syndrome mimicking relapse of AIDS related lymphoma in patients with HIV 1 infection","volume":"44","author":"Powles","year":"2003","journal-title":"Leuk Lymphoma"},{"key":"10.1157\/13123842_bb0895","first-page":"181","article-title":"Lung cancer as an immune reconstitution disease in an HIV-1 positive man receiving HAART","volume":"60","author":"Knysz","year":"2006","journal-title":"Postepy Hig Med Dosw (Online)"},{"key":"10.1157\/13123842_bb0900","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1016\/j.semarthrit.2005.03.007","article-title":"Rheumatic complications of human immunodeficiency virus infection in the era of highly active antiretroviral therapy: Emergence of a new syndrome of immune reconstitution and changing patterns of disease","volume":"35","author":"Calabrese","year":"2005","journal-title":"Semin Arthritis Rheum"},{"key":"10.1157\/13123842_bb0905","doi-asserted-by":"crossref","first-page":"466","DOI":"10.1097\/01.aids.0000196173.42680.5f","article-title":"Graves disease: An increasingly recognized immune reconstitution syndrome","volume":"20","author":"Crum","year":"2006","journal-title":"AIDS"},{"key":"10.1157\/13123842_bb0910","doi-asserted-by":"crossref","first-page":"1159","DOI":"10.1086\/383034","article-title":"Immune reconstitution in HIV-infected patients","volume":"38","author":"Hirsch","year":"2004","journal-title":"Clin Infect Dis"},{"key":"10.1157\/13123842_bb0915","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1093\/jac\/dki444","article-title":"Immune reconstitution inflammatory syndrome: more answers, more questions","volume":"57","author":"Shelburne","year":"2006","journal-title":"J Antimicrob Chemother"},{"key":"10.1157\/13123842_bb0920","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1080\/13550280152537247","article-title":"The good and the evil of HAART in HIV-related progressive multifocal leukoencephalopathy","volume":"7","author":"Cinque","year":"2001","journal-title":"J Neurovirol"},{"key":"10.1157\/13123842_bb0925","doi-asserted-by":"crossref","first-page":"1043","DOI":"10.1097\/01.aids.0000174450.70874.30","article-title":"Incidence and risk factors of immune reconstitution inflammatory syndrome complicating HIV-associated cryptococcosis in France","volume":"19","author":"Lortholary","year":"2005","journal-title":"AIDS"},{"key":"10.1157\/13123842_bb0930","doi-asserted-by":"crossref","first-page":"e7","DOI":"10.1086\/518699","article-title":"Methotrexate treatment for type 1 (reversal) leprosy reactions","volume":"45","author":"Biosca","year":"2007","journal-title":"Clin Infect Dis"},{"key":"10.1157\/13123842_bb0935","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1097\/00002030-200401230-00015","article-title":"A study of the safety, immunology, virology, and microbiology of adjunctive etanercept in HIV-1-associated tuberculosis","volume":"18","author":"Wallis","year":"2004","journal-title":"AIDS"},{"key":"10.1157\/13123842_bb0940","doi-asserted-by":"crossref","first-page":"1859","DOI":"10.1097\/00002030-200008180-00026","article-title":"Clinical and immunological benefit of adjuvant therapy with thalidomide in the treatment of tuberculosis disease","volume":"14","author":"Gori","year":"2000","journal-title":"AIDS"},{"key":"10.1157\/13123842_bb0945","doi-asserted-by":"crossref","first-page":"446","DOI":"10.5694\/j.1326-5377.1997.tb123204.x","article-title":"Pentoxifylline to treat Mycobacterium avium complex exacerbation in late-stage HIV infection","volume":"166","author":"Reeves","year":"1997","journal-title":"Med J Aust"},{"key":"10.1157\/13123842_bb0950","first-page":"1","article-title":"Treating Opportunistic Infections Among HIV-Infected Adults and Adolescents: recommendations from CDC, the National Institutes of Health, and the HIV Medicine Association\/Infectious Diseases Society of America","volume":"53","author":"Centers for Disease Control and Prevention","year":"2004","journal-title":"MMWR"}],"container-title":["Enfermedades Infecciosas y Microbiolog\u00eda Cl\u00ednica"],"original-title":[],"language":"es","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0213005X08727277?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0213005X08727277?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,5,16]],"date-time":"2019-05-16T22:05:51Z","timestamp":1558044351000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0213005X08727277"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2008,7]]},"references-count":189,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2008,7]]}},"alternative-id":["S0213005X08727277"],"URL":"https:\/\/doi.org\/10.1157\/13123842","relation":{},"ISSN":["0213-005X"],"issn-type":[{"value":"0213-005X","type":"print"}],"subject":[],"published":{"date-parts":[[2008,7]]}}}